We identified in the CANTON trial actually quite a number of patients that we would now consider glioblastoma because of their molecular makeup. Histologically they are still grade 3, but they have the features that we now understand as features of glioblastoma. And we looked in depth in what the outcome of these patients was in the CANTON trial. And we absolutely do not see any benefit of temozolomide...
We identified in the CANTON trial actually quite a number of patients that we would now consider glioblastoma because of their molecular makeup. Histologically they are still grade 3, but they have the features that we now understand as features of glioblastoma. And we looked in depth in what the outcome of these patients was in the CANTON trial. And we absolutely do not see any benefit of temozolomide. And neither in the patients with, neither in the entire population, nor in the patients with MGMT promoter methylation. And we don’t really have an explanation for this. And at this point in time, I don’t think we have made therapeutic advances. We know that radiation therapy works. Most of us will give chemotherapy. But probably improvement in treatment in those patients will come from improvement of treatment of patients with glioblastoma. and we haven’t reached that yet.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
